Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer

Medical Science Monitor

Volumn 8, Issue 9, 2002, Pages

  Tsavaris, Nicolas ^a   Kosmas, Christos ^a   Gennatas, Kostas ^a   Vadiaka, Maria ^a   Paliaros, Platon ^a   Dimitrakopoulos, Antonis ^a   Diamantis, Theodoros ^a   Tsipras, Heraklis ^a   Papastratis, George ^a  

^a METAXA CANCER HOSPITAL   (Greece)

Author keywords

Colorectal cancer; Etoposide; Fluorouracil; Leucovorin

Indexed keywords

ETOPOSIDE; FLUOROURACIL; FOLINIC ACID;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NEUTROPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; ETOPOSIDE; FLUOROURACIL; HUMANS; LEUCOVORIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 18344419168     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Wilke H, Preusser P, Fink U et al: High-dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer - a phase II study in elderly patients or patients with cardiac risk. Invest New Drugs, 1990; 8: 65-70
2. Norum J, Angelsen V: Chemotherapy in gastric cancer: an economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin-C) versus ELF (etoposide, leucovorin, 5-fluorouracil) regimens. J Chemother, 1995; 7: 455-459
3. Van Cutsem E, Filez L, Dewyspelaere J et al: Etoposide, leucovorin and 5-fluorouracil in advanced gastric cancer: a phase II study. Anticancer Res, 1995; 15: 1079-1080
4. di Bartolomeo M, Bajetta E, de Braud F et al: Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. Oncology, 1995; 52: 41-44
5. Taal BG, Teller FG, ten Bokkel Huinink WW et al: Etoposide, leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide. Ann Oncol, 1994; 5: 90-92
6. Adamo V, Scimone A, Maisano R et al: Etoposide, 1-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother, 1999; 11: 74-77
7. Chiou TJ, Tung SL, Hsieh RK et al: Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer. Jpn J Clin Oncol, 1998; 28: 318-322
8. Au E, Koo WH, Tan EH, Ang PT: A phase II trial of etoposide, leucovorin and 5-fluorouracil (ELF) in patients with advanced gastric cancer. J Chemother, 1996; 8: 300-303
9. Planting AS, van der Burg ME, van den Bent MJ et al: Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer. Br J Cancer, 1996; 73: 1265-1267
10. Passalacqua R, Bisagni G, Cocconi G et al: Cisplatin and etoposide in advanced colorectal carcinoma. Ann Oncol, 1991; 2: 687-688
11. Posner M, Slapak CA, Browne MJ et al: A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal cancer. Am J Clin Oncol, 1990; 13: 455-458
12. Colucci G, Maiello E, Giuliani F et al: Carboplatin and etoposide in previously treated colorectal cancer patients. Tumori, 1995; 81: 36-38
13. Zelkowitz RS, Posner MR, Cummings F et al: A Phase I/II trial of 5-fluorouracil and etoposide in metastatic colorectal carcinoma. Am J Clin Oncol, 189; 12: 492-493
14. Stuart K, Posner M, Campbell K, Huberman M: Cisplatin and chronic oral etoposide as salvage therapy for advanced colorectal carcinoma. Am J Clin Oncol, 1995; 18: 300-302
15. Inaba M, Mitsuhashi J, Kawada S, Nakano H: Different modes of cell killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis. Jpn J Cancer Res, 1994; 85: 187-193
16. Sinkule JA: Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent. Pharmacotherapy, 1984; 4: 61-73
17. Jeremic B, Acintovic L, Mijatovic L: Carboplatin and etoposide in advanced colorectal carcinoma. A phase II study. Cancer, 1993; 71: 2706-2708
18. Zaniboni A, Labianca R, Pancera G et al: Oral etoposide as secondline chemotherapy for colorectal cancer: a GISCAD study. Gruppo Italiano Studio Carcinomi Apparato Digerente. J Chemother, 1995; 7: 246-248
19. Miller A, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer, 1981; 47: 207-217
20. Kaplan EL, Meier P: Non parametric estimation for incomplete observations. J Am Stat Assoc, 1958; 53: 457-481
21. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep, 1966; 50: 163-170
22. Cunningham D, Pyrhonen S, James RD et al: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 1998; 352: 1413-1418
23. Rougier P, Van Cutsem E, Bajetta E et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 1998; 352: 1407-1412
24. Macdonald JS, Kisner DF, Smythe T et al: 5-fluorouracil (5-FU), methyl-CCNU and vincristine in the treatment of advanced colorectal cancer: phase II study utilizing weekly 5-FU. Cancer Treat Rep, 1976; 60: 1597-1602
25. Moertel CG, Schutt AJ, Hahn RG, Reitemeier RJ: Therapy of advanced colorectal cancer with a combination of 5-fluorouracil, methyl-3-cis(2-chlorethyl)-1-nitrosourca and vincristine. J Natl Cancer Inst, 1975; 54: 67-74
26. Kemeny N, Yagoda A, Braun D Jr, Galbey R: Randomized study of 2 different schedules of methyl-CCNU, 5-FU, and vincristine for metastatic colorectal carcinoma. Cancer, 1979; 43: 78-83
27. Posey L, Morgan LR: Methyl-CCNU versus methyl-CCNU and 5- fluorouracil in carcinoma of the large bowel. Cancer Treat Rep, 1977; 61: 1453-1459
28. Baker LH, Talley RW, Matter R et al: Phase II comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU versus methyl-CCNU plus bolus weekly 5-FU: a Southwest Oncology Group study. Cancer, 1976; 38: 1-7
29. Kemeny N, Yagoda A, Braun J: Metastatic colorectal carcinoma: A prospective trial of methyl CCNU, 5-fluorouracil (5FU) and vincristine (MOF) versus MOF plus streptozotocin (MOF-Strep). Cancer, 1983; 51: 20-25
30. Andre T, Lonvet C, Raymond E et al: Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regiment. Ann Oncol, 1998; 9: 1251-1253
31. Tournigand C, Louvet C, Quinaux E et al: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): final results of a phase III study. Proc Am Soc Clin Oncol, 2001; 20: 124a (abstr 494)
32. Tsavaris N, Tentas K, Bacoyiannis C et al: 5-fluorouracil, folonic acid and cisplatin in advanced colorectal cancer: a pilot study. Anti-Cancer Drugs, 1995; 6: 599-603
33. Diaz-Rubio E, Jimeno J, Anton A et al: A prospective randomized trial of continuous infusion 5-fluorouracil versus 5-fluorouracil plus cisplatin in patients with advanced colorectal cancer. Am J Clin Oncol, 1992; 15: 56-60